The primary analysis of the phase 3 HARMONi-2 trial will be featured as part of the Presidential Symposium at the IASLC 2024 World Conference on Lung Cancer in San Diego, California, according to an announcement from Summit Therapeutics Inc.
Dr. Caicun Zhou, chief physician and director of the Department of Medical Oncology at Shanghai Pulmonary Hospital, Tongji University School of Medicine, and president-elect of IASLC, will present results of the primary analysis at 8:37 am PDT on Sunday, September 8.
The phase 3 HARMONi-2 study evaluated ivonescimab monotherapy and compared it with pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have tumors with positive PD-L1 expression. The single-region, multicenter, double-blinded trial was conducted in China.
Officials announced in May 2024 that the HARMONi-2 trial showed ivonescimab “achieved a statistically significant improvement in the trial’s primary end point,” which was progression-free survival (PFS), compared with pembrolizumab. The PFS benefit was demonstrated across clinical subgroups, including those with PD-L1–low expression, PD-L1–high expression, and squamous and nonsquamous histology, as well as other high-risk patients, according to the announcement.
This result is notable because “there are no known phase 3 clinical trials in NSCLC that have shown a statistically significant efficacy improvement compared [with] pembrolizumab in a head-to-head setting,” officials said in the announcement.
The IASLC 2024 World Conference on Lung Cancer will also feature a presentation by Xiaoliang Zhao, MD, that includes data from the phase 2 AK112-205 trial. That presentation, titled “A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer,” will be held at 11:17 am PDT on Sunday, September 8.
Source: BusinessWire
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.